Eating disorders affect an estimated 1.25 million people in the UK, according to the charity Beat. Women and girls are disproportionately affected — approximately 75% of those diagnosed with anorexia nervosa and bulimia nervosa are female, though male cases are increasingly recognised and likely under-reported.
Community pharmacy teams occupy a unique position in the early identification of eating disorders. Regular dispensing contact, OTC sales patterns, and visible physical changes can all provide early warning signs that may not be apparent in infrequent GP consultations.
The renewed Women's Health Strategy, announced on 15 April 2026, calls for women's health concerns to be taken seriously across all healthcare settings. Eating disorders — frequently dismissed, minimised, or missed entirely — are a prime example of where that commitment needs to translate into frontline action.
Types of eating disorder
| Disorder | Key features | Pharmacy-relevant signs |
|---|---|---|
| Anorexia nervosa | Restriction of food intake, intense fear of weight gain, distorted body image | Visible weight loss, purchasing diet products, cold intolerance (requesting heating pads, thermal products) |
| Bulimia nervosa | Binge eating followed by purging (vomiting, laxative misuse, excessive exercise) | Frequent laxative purchases, dental erosion, swollen parotid glands, calluses on knuckles |
| Binge eating disorder | Recurrent binge episodes without compensatory purging | May purchase large quantities of antacids; weight gain |
| OSFED (Other Specified Feeding or Eating Disorder) | Clinically significant but doesn't meet full criteria for above | Mixed presentation; any of the above signs |
| ARFID (Avoidant/Restrictive Food Intake Disorder) | Restricted range of foods, not driven by body image concerns | Nutritional supplement purchases, vitamin deficiency presentations |
What pharmacy teams may notice
OTC purchasing patterns
The single strongest pharmacy-identifiable signal is laxative misuse. Regular purchase of stimulant laxatives (senna, bisacodyl) in quantities or frequencies inconsistent with normal constipation treatment should raise concern — particularly in young women.
Other OTC patterns to note:
- Diet pills and appetite suppressants — particularly if purchased by someone who appears underweight
- Ipecac syrup — historically used to induce vomiting (no longer widely available but occasionally requested)
- Excessive vitamin and mineral supplement purchases — may indicate restricted diet
- Throat lozenges and antacids — frequent purchase may reflect purging-related throat irritation
- Potassium and electrolyte supplements — may indicate awareness of purging-related electrolyte depletion
Prescription patterns
Pharmacists dispensing repeat prescriptions may notice:
- Prescriptions for potassium supplements or oral rehydration salts
- Frequent antiemetic or prokinetic prescriptions
- Oral contraceptive pill prescribed alongside very low BMI (amenorrhoea treatment)
- SSRI prescriptions at higher doses (fluoxetine 60 mg is specifically licensed for bulimia)
Physical signs
Regular patients who show rapid, visible weight loss, dental erosion, dry skin, lanugo hair (fine downy hair on the face and arms), or parotid gland swelling warrant a sensitive conversation.
How to raise the concern
Eating disorders carry intense shame and secrecy. A clumsy intervention can drive the patient away from the pharmacy entirely. NICE guidelines (NG69) recommend:
- Create a private opportunity. "Would you like to step into the consultation room?" The counter is never the right place for this conversation.
- Ask with curiosity, not accusation. "I've noticed you've been buying laxatives quite regularly — are you finding they're not working as well?" is better than "Are you misusing laxatives?"
- Normalise help-seeking. "A lot of people find it hard to talk about these things. There are specialist services that can help, and your GP is a good starting point."
- Provide information. Beat's helpline (0808 801 0677) and website offer confidential support. Printed information left in consultation rooms allows patients to take it without asking.
- Do not comment on weight or appearance. "You look thin" or "You've lost weight" can reinforce disordered thinking regardless of intent.
- Document and refer if concerned. A pharmacist who suspects an eating disorder can contact the patient's GP directly (with or without the patient's consent if there is a safeguarding concern, particularly for under-18s).
The laxative conversation
Laxative misuse is the most pharmacist-actionable eating disorder signal. Stimulant laxatives (senna, bisacodyl) are the most commonly misused, but osmotic laxatives (macrogol, lactulose) may also be purchased in excessive quantities.
Pharmacy teams should be aware that:
- Laxative misuse does not cause meaningful calorie malabsorption — most nutrient absorption occurs in the small intestine, before laxatives act
- Chronic stimulant laxative use causes melanosis coli, electrolyte imbalance (particularly hypokalaemia), and rebound constipation
- Abrupt cessation after chronic misuse can cause severe constipation and bloating, which may trigger relapse — tapering under medical supervision is recommended
The Medicines and Healthcare products Regulatory Agency (MHRA) requires that OTC stimulant laxatives carry warnings against prolonged use. Pharmacy teams can use this as a conversation starter: "The label advises short-term use only — have you spoken to your GP about the ongoing constipation?"
Data context
PharmSee tracks 1,742 active pharmacy vacancies across England. Eating disorder awareness is not typically listed as a specific competency in pharmacy job descriptions, but it falls within the GPhC's Standards for Pharmacy Professionals requirement to safeguard vulnerable patients. CPPE offers a free online learning module on eating disorders for pharmacy teams.
For pharmacies near you offering consultation room access, use PharmSee's pharmacy finder.
Caveats
Prevalence data is from the eating disorder charity Beat and the Adult Psychiatric Morbidity Survey. Individual pharmacy purchasing data is not available through PharmSee. The link between OTC purchasing patterns and eating disorders is observational and should prompt sensitive enquiry, not diagnosis.
Sources: Beat Eating Disorders, NICE NG69, GPhC Standards for Pharmacy Professionals, MHRA OTC labelling requirements, CPPE learning resources, PharmSee vacancy database (April 2026), BBC News (15 April 2026).